- Home
- AREB vs ZVSA Comparison
AREB vs ZVSA Comparison
Compare AREB & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AREB
- ZVSA
- Stock Information
- Founded
- AREB 2014
- ZVSA 2014
- Country
- AREB United States
- ZVSA United States
- Employees
- AREB N/A
- ZVSA N/A
- Industry
- AREB Plastic Products
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- AREB Industrials
- ZVSA Health Care
- Exchange
- AREB Nasdaq
- ZVSA Nasdaq
- Market Cap
- AREB 2.7M
- ZVSA 2.3M
- IPO Year
- AREB N/A
- ZVSA N/A
- Fundamental
- Price
- AREB $2.52
- ZVSA $1.08
- Analyst Decision
- AREB
- ZVSA Strong Buy
- Analyst Count
- AREB 0
- ZVSA 1
- Target Price
- AREB N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- AREB 1.8M
- ZVSA 3.6M
- Earning Date
- AREB 11-12-2024
- ZVSA 11-14-2024
- Dividend Yield
- AREB N/A
- ZVSA N/A
- EPS Growth
- AREB N/A
- ZVSA N/A
- EPS
- AREB N/A
- ZVSA N/A
- Revenue
- AREB $15,454,870.00
- ZVSA N/A
- Revenue This Year
- AREB $45.19
- ZVSA N/A
- Revenue Next Year
- AREB N/A
- ZVSA N/A
- P/E Ratio
- AREB N/A
- ZVSA N/A
- Revenue Growth
- AREB N/A
- ZVSA N/A
- 52 Week Low
- AREB $1.90
- ZVSA $1.05
- 52 Week High
- AREB $9.27
- ZVSA $42.35
- Technical
- Relative Strength Index (RSI)
- AREB 41.27
- ZVSA 27.91
- Support Level
- AREB $2.76
- ZVSA $1.34
- Resistance Level
- AREB $3.33
- ZVSA $1.89
- Average True Range (ATR)
- AREB 0.40
- ZVSA 0.25
- MACD
- AREB 0.03
- ZVSA -0.08
- Stochastic Oscillator
- AREB 12.14
- ZVSA 1.29
About AREB American Rebel Holdings Inc.
American Rebel Holdings Inc develops self-defense, safe storage, and patriotic products. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, vault doors, and Others.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.